Adalimumab/golimumab/infliximabCytomegalovirus infection, development of anti-drug antibodies and lack of efficacy: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1885卷 / 1期

关键词：

D O I：

10.1007/s40278-021-06787-8

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：28 / 28

相关论文

共 50 条

[1] Adalimumab/etanerceptNeutralising anti-drug antibodies and lack of efficacy: case report
Reactions Weekly, 2021, 1844 (1) : 19 - 19
[2] Adalimumab/methotrexateLack of efficacy and development of anti-drug antibodies : case report
Reactions Weekly, 2018, 1724 (1) : 18 - 18
[3] Factors that may influence the development of anti-drug antibodies to adalimumab
Reinisch, W.
Rauter, I.
Chen, L.
Gessner, M.
Fanjiang, G.
JOURNAL OF CROHNS & COLITIS, 2019, 13 : S429 - S430
[4] Adalimumab/infliximabDevelopment of anti-drug antibodies: 7 case reports
Reactions Weekly, 2018, 1701 (1) : 15 - 15
[5] InfliximabFormation of anti-drug antibodies: case report
Reactions Weekly, 2022, 1918 (1) : 270 - 270
[6] EmicizumabDevelopment of anti-drug antibodies: case report
Reactions Weekly, 2023, 1947 (1) : 172 - 172
[7] GolimumabDevelopment of anti-drug antibodies: case report
Reactions Weekly, 2019, 1749 (1) : 199 - 199
[8] AdalimumabDevelopment of anti-drug antibodies: case report
Reactions Weekly, 2022, 1925 (1) : 21 - 21
[9] InfliximabDeveloped anti-drug antibodies to infliximab: case report
Reactions Weekly, 2018, 1714 (1) : 227 - 227
[10] Adalimumab/certolizumab-pegolDevelopment of anti-drug antibodies: 2 case reports
Reactions Weekly, 2020, 1800 (1) : 16 - 16

← 1 2 3 4 5 →